Matches in SemOpenAlex for { <https://semopenalex.org/work/W4294292849> ?p ?o ?g. }
Showing items 1 to 62 of
62
with 100 items per page.
- W4294292849 endingPage "IA19" @default.
- W4294292849 startingPage "IA19" @default.
- W4294292849 abstract "Abstract Single agent anti PD-1 antibodies have shown consistent safety and efficacy for the treatment of advanced hepatocellular carcinoma (HCC). Response rates range between 15 and 20% and the rate of grade 3 and 4 adverse events is generally below 25%. Recently, the HIMALAYA trial showed that durvalumab was non-inferior to sorafenib for first-line treatment of HCC. Further, Keynote-394 showed that pembrolizumab improved survival compared to placebo in second line treatment of HCC. Nivolumab was evaluated in a dedicated cohort of Checkmate 040 in patients with child pugh B cirrhosis and determined to have a manageable safety profile, similar to that in child pugh A. Given the fact that immunotherapy-based combinations are the current standard of care for advanced HCC, and given the absence of biomarkers for patient selection, the use of single agent anti PD-1 or PD-L1 antibodies in advanced first line HCC treatment is limited to patients who are not candidates for combination therapy or patients with compromised liver function. Single agent anti PD-1/PD-L1 antibodies are being evaluated in the adjuvant setting and in combination with liver directed therapy. Emerging biomarker data suggest an association between T cell inflammation signature and outcome with single agent anti PD-1 and PD-L1 agents. Further research is needed to validate the early biomarker data. Citation Format: Anthony El-Khoueiry. Impact of single checkpoint inhibitors and biomarkers of response [abstract]. In: Proceedings of the AACR Special Conference: Advances in the Pathogenesis and Molecular Therapies of Liver Cancer; 2022 May 5-8; Boston, MA. Philadelphia (PA): AACR; Clin Cancer Res 2022;28(17_Suppl):Abstract nr IA19." @default.
- W4294292849 created "2022-09-02" @default.
- W4294292849 creator A5013744957 @default.
- W4294292849 date "2022-09-01" @default.
- W4294292849 modified "2023-09-26" @default.
- W4294292849 title "Abstract IA19: Impact of single checkpoint inhibitors and biomarkers of response" @default.
- W4294292849 doi "https://doi.org/10.1158/1557-3265.liverca22-ia19" @default.
- W4294292849 hasPublicationYear "2022" @default.
- W4294292849 type Work @default.
- W4294292849 citedByCount "0" @default.
- W4294292849 crossrefType "journal-article" @default.
- W4294292849 hasAuthorship W4294292849A5013744957 @default.
- W4294292849 hasConcept C121608353 @default.
- W4294292849 hasConcept C126322002 @default.
- W4294292849 hasConcept C143998085 @default.
- W4294292849 hasConcept C185592680 @default.
- W4294292849 hasConcept C197934379 @default.
- W4294292849 hasConcept C2775949291 @default.
- W4294292849 hasConcept C2777701055 @default.
- W4294292849 hasConcept C2777742743 @default.
- W4294292849 hasConcept C2778019345 @default.
- W4294292849 hasConcept C2778695046 @default.
- W4294292849 hasConcept C2780030458 @default.
- W4294292849 hasConcept C2780057760 @default.
- W4294292849 hasConcept C2781197716 @default.
- W4294292849 hasConcept C55493867 @default.
- W4294292849 hasConcept C71924100 @default.
- W4294292849 hasConceptScore W4294292849C121608353 @default.
- W4294292849 hasConceptScore W4294292849C126322002 @default.
- W4294292849 hasConceptScore W4294292849C143998085 @default.
- W4294292849 hasConceptScore W4294292849C185592680 @default.
- W4294292849 hasConceptScore W4294292849C197934379 @default.
- W4294292849 hasConceptScore W4294292849C2775949291 @default.
- W4294292849 hasConceptScore W4294292849C2777701055 @default.
- W4294292849 hasConceptScore W4294292849C2777742743 @default.
- W4294292849 hasConceptScore W4294292849C2778019345 @default.
- W4294292849 hasConceptScore W4294292849C2778695046 @default.
- W4294292849 hasConceptScore W4294292849C2780030458 @default.
- W4294292849 hasConceptScore W4294292849C2780057760 @default.
- W4294292849 hasConceptScore W4294292849C2781197716 @default.
- W4294292849 hasConceptScore W4294292849C55493867 @default.
- W4294292849 hasConceptScore W4294292849C71924100 @default.
- W4294292849 hasIssue "17_Supplement" @default.
- W4294292849 hasLocation W42942928491 @default.
- W4294292849 hasOpenAccess W4294292849 @default.
- W4294292849 hasPrimaryLocation W42942928491 @default.
- W4294292849 hasRelatedWork W2745896026 @default.
- W4294292849 hasRelatedWork W2802256694 @default.
- W4294292849 hasRelatedWork W2923986778 @default.
- W4294292849 hasRelatedWork W2969038597 @default.
- W4294292849 hasRelatedWork W2981562389 @default.
- W4294292849 hasRelatedWork W3000961096 @default.
- W4294292849 hasRelatedWork W3019495616 @default.
- W4294292849 hasRelatedWork W3119432592 @default.
- W4294292849 hasRelatedWork W3154458198 @default.
- W4294292849 hasRelatedWork W4281682363 @default.
- W4294292849 hasVolume "28" @default.
- W4294292849 isParatext "false" @default.
- W4294292849 isRetracted "false" @default.
- W4294292849 workType "article" @default.